The potential clinical value of a noninvasive biomarker for acute rejection and borderline changes in stable kidney transplant patients is not universal. The use of noninvasive biomarkers for subclinical rejection depends on the frame of reference-on center practice of performing or not performing surveillance kidney allograft biopsies.
| SURVEILL AN CE B I OPSY PR AC TICE IN KIDNE Y TR ANS PL ANTATION
In 2006, an international consensus group concluded that "the debate is not whether surveillance biopsies reveal subclinical important diseases and mechanisms, but whether their safety justifies the gain."
1 Surveillance biopsies are aimed to identify subclinical pathologic findings with prognostic value that can be successfully treated. The problem here is that neither the prognostic value nor the treatment of the majority of those so-called subclinical lesions are universally accepted. In a recent survey, 17% of centers in the United States perform surveillance biopsies on all patients, and 21% perform surveillance biopsies in select cases. Conversely, 62% of centers do not perform surveillance biopsies, only biopsies for cause (eg, rise in serum creatinine or proteinuria).
2 Clinical standards to perform or to not perform surveillance biopsies depend on the reference frame by which the centers approach the importance of detecting this subclinical injury. Centers that do not perform surveillance biopsies report logistic reasons like inadequate staffing and insurance barriers but also aspects of "low yield" and "will not change outcome." In contrast, almost all centers that perform surveillance biopsies treat subclinical episodes of rejection. This illustrates that these centers do change clinical practice based on the surveillance biopsy results, despite the absence of strong evidence for this. 2 More and better studies are needed on this topic and subsequent consensus in our community.
| D IAG NOS TI C B I OMARK ER S FOR ACUTE RE JEC TI ON
The interest in surveillance biopsies in kidney transplantation reflects the movement toward precision medicine. 3 In precision medicine, which tries to be proactive and preventative, repeated assessment of ongoing subclinical injury is central. The diagnostic performance of the multigene marker for borderline changes/TCMR was remarkably good (area under the receiver operating characteristic curve, 85%) in the discovery set. Moreover, the study included external validation of the multigene model and of the proposed diagnostic threshold. 5 For these reasons, the CTOT-08 study is a landmark study in this field, with a flawless study design, in contrast to previous studies that lacked straightforward inclusion criteria, lacked external validation, lacked fixation of the algorithms, or had small sample size.
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| REL ATIVIT Y OF THE THRE S HOLDS FOR A NONINVA S IVE D IAG NOS TI C B IOMARKER
Despite the impressive efforts to accomplish this analysis and the vast amount of information offered, the CTOT-08 study 5 unavoidably raises some questions and concerns. Center differences in the implementation of surveillance biopsy programs have an impact on the potential clinical use of this biomarker for subclinical kidney transplant injury (Figure 1 ).
The CTOT-08 investigators conclude that their 57-gene biomarker and its arbitrary diagnostic threshold could help in excluding ongoing subclinical rejection and reduce the indiscriminate use of invasive surveillance biopsies. 5 This 57-gene biomarker is thus positioned as noninvasive biomarker for immune quiescence and could be relevant for the minority of centers that routinely
The special relativity of diagnostic thresholds for detection of subclinical injury in kidney transplantation. A, The majority of centers do not perform surveillance biopsies. These centers do not need a biomarker to tell them when not to perform a biopsy.
A biomarker for histological injury in patients with stable graft function would need to provide these centers a new indication for performing a kidney transplant biopsy. Detection of subclinical injury could be valuable also for these centers, but the background reference frame makes it unlikely that they will use a biomarker that leads to many false-positive results. False-positive results would lead to unnecessary anxiety, logistic issues, and additional risk to the patients and costs, which are prime reasons why these centers are currently not performing surveillance biopsies. For these centers, a biomarker for detection of subclinical disease should have high positive predictive values (PPVs). B, In contrast, centers that routinely perform surveillance biopsies consider that the clinical benefits for the patients outweigh the logistic burden and risks associated with the surveillance biopsy program. A biomarker to help decide which patients have very little chance of ongoing subclinical injury, could be of use for these centers, in trying to diminish this logistic burden, costs, and risks. However, these centers will only be convinced of the value of such a biomarker if the number of cases that are missed remains small. In other words, the number of false-negative cases should be low, which translates into high negative predictive values (NPV) and high sensitivity perform surveillance biopsies. However, while the negative predictive value with the proposed threshold was 78% to 80% in the validation set, the sensitivity on this cohort was only 48% (22/42).
More than half of the cases with ongoing rejection were missed by the biomarker. Whether this will be sufficient to convince clinicians of the value of this multigene marker to exclude subclinical rejection is unclear. Setting the diagnostic threshold lower, to avoid false-negative results, and thus increase sensitivity, could have been considered according to the results of the discovery set, but this scenario was not tested in the independent cohort.
Furthermore, as the value of surveillance biopsies for clinical routine is still on debate, a test aimed to avoid such surveillance biopsies seems futile for the majority of transplant centers that do not perform them. In such centers, the proposed 57-gene biomarker cannot be used to positively diagnose ongoing rejection (ie, to suggest subclinical rejection and indicate performing a kidney transplant biopsy). Half of the cases (49%; 19/39) in the validation cohort of the CTOT-08 report that fell above the arbitrarily selected threshold for rejection of the 57-gene biomarker did not have rejection on their biopsy. 5 Setting the diagnostic threshold higher, with a higher positive predictive value, does not seem to solve this problem, as the higher thresholds were associated with very low sensitivity, even in the discovery cohort.
| FURTHER DE VELOPMENT AND VALORIZ ATION
Next to these questions about the best threshold and caution to the correct clinical implementation, several other aspects will become relevant in further development and potential valorization of the CTOT-08 multigene marker.
Of the 742 biopsies included in the study, 191 were clinically indicated but were not included in the analyses. 5 Given that for-cause biopsies often have the same histology as surveillance biopsies, it will become important to see whether the biomarker reflects histological lesions, independent of graft function. Also, rejection is not an on-off phenomenon, and it will be relevant to evaluate whether false-negative results (missed cases) were mainly observed in patients with borderline changes or also in TCMR.
Next, it was not tested whether the CTOT-08 biomarker is sufficiently sensitive for antibody-mediated rejection (ABMR). 5 If this biomarker is to be used to avoid surveillance biopsies in patients at low probability of subclinical rejection, it should not miss cases with subclinical ABMR, which is associated with worse outcome than subclinical TCMR. Finally, the prevalence of subclinical tubulointerstitial inflammation evolves over time after transplant. 8 Although sensitivity and specificity of a test are independent of disease prevalence, positive and negative predictive values are highly dependent on disease prevalence. It is therefore possible that posttransplant timing has an impact on biomarker performance. Additional insight into the accuracy metrics of the biomarker over time after transplant will also be helpful in its further development.
| CON CLUS ION
In summary, as our community lacks consensus on the value of surveillance biopsies after kidney transplant, the potential clinical value of the 57-gene biomarker developed by the CTOT-08 consortium is relative to the frame of reference, regardless of whether a center performs surveillance biopsies. Additional work on establishing the best diagnostic threshold seems important for eventual further valorization. A biomarker with low positive predictive value and low specificity will not help in detecting ongoing disease. Conversely, a biomarker with low sensitivity may be insufficient to exclude disease. Or, as the inventor of special relativity would have said, "If you judge a fish by its ability to climb a tree, it will live its whole life believing that it is stupid."
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